Mega Lifesciences (MEGA) Hisse Özeti
Mega Lifesciences Public Company Limited, iştirakleri ile birlikte Güneydoğu Asya ve Sahra Altı Afrika'da sağlıklı gıda takviyeleri, reçeteli farmasötik ürünler, reçetesiz ürünler, bitkisel ürünler, vitaminler ve hızlı tüketim malları üretmekte ve satmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 4/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 4/6 |
MEGA Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Mega Lifesciences Public Company Limited Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | ฿35.25 |
| 52 Haftanın En Yüksek Seviyesi | ฿40.00 |
| 52 Haftanın En Düşük Seviyesi | ฿24.60 |
| Beta | 0.32 |
| 1 Aylık Değişim | -3.42% |
| 3 Aylık Değişim | -1.40% |
| 1 Yıllık Değişim | 39.60% |
| 3 Yıllık Değişim | -11.32% |
| 5 Yıllık Değişim | 0.71% |
| Halka arzdan bu yana değişim | 65.49% |
Son Haberler & Güncellemeler
MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside
Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).
MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued
Analysts have lifted their price target on Mega Lifesciences from THB 32 to THB 35, citing updated assumptions around higher revenue growth, a slightly lower discount rate and a revised future P/E multiple, partially offset by a more conservative profit margin outlook. What's in the News Board meeting scheduled for Feb 24, 2026, to consider a dividend payment proposal for the year ended Dec 31, 2025 (company filing).MEGA: Stable Outlook And Upcoming Dividend Decision Will Support Upside
Analysts have maintained their price target for Mega Lifesciences at THB41.17, citing unchanged assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).Recent updates
MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside
Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued
Analysts have lifted their price target on Mega Lifesciences from THB 32 to THB 35, citing updated assumptions around higher revenue growth, a slightly lower discount rate and a revised future P/E multiple, partially offset by a more conservative profit margin outlook. What's in the News Board meeting scheduled for Feb 24, 2026, to consider a dividend payment proposal for the year ended Dec 31, 2025 (company filing).MEGA: Stable Outlook And Upcoming Dividend Decision Will Support Upside
Analysts have maintained their price target for Mega Lifesciences at THB41.17, citing unchanged assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).MEGA: Higher Fair Value And Upcoming Dividend Decision Will Support Upside
Analysts have lifted their fair value estimate for Mega Lifesciences from THB 38.21 to THB 41.17, citing updated assumptions for long term profit margins and a higher future P/E multiple. What's in the News A board meeting is scheduled for February 24, 2026 for Mega Lifesciences Public Company Limited.
MEGA: Higher Future P/E Will Support Upgraded Fair Value Outlook
Analysts have lifted their price target for Mega Lifesciences from THB 41.60 to THB 45.00. They highlighted updated assumptions that include slightly lower revenue growth and profit margins, together with a higher future P/E multiple.MEGA: Updated Discount Rate And Margins Will Support Fair Pricing Ahead
Analysts have raised their price target on Mega Lifesciences to THB 38.21 from THB 34.58, citing updated assumptions related to slightly lower discount rates, adjusted revenue growth, modestly different profit margins and a revised future P/E multiple. Valuation Changes Fair Value: THB 34.58 to THB 38.21, indicating a modest uplift in the assessed share valuation.MEGA: Fair Outlook Will Balance Softer Margins With Stronger Revenue Expectations
Narrative update on Mega Lifesciences The analyst price target for Mega Lifesciences has been lifted from ฿39.00 to ฿41.60, with analysts linking this change to updated assumptions for slightly lower discount rates, higher forecast revenue growth, a modestly softer profit margin, and a higher future P/E multiple. Valuation Changes Fair Value Estimate: Raised from THB 39.00 to THB 41.60, a small uplift in the assessed equity value.MEGA: Stable Assumptions And Margins Will Support Fair Pricing Ahead
The analyst price target for Mega Lifesciences remains unchanged at ฿34.58, with analysts citing consistent assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Valuation Changes Fair value: Unchanged at THB34.58 per share, with no adjustment to the underlying assumptions.MEGA: Higher Margin Assumptions Will Likely Leave Shares Overvalued
The analyst fair value estimate for Mega Lifesciences has been adjusted from ฿26.00 to ฿32.00, with analysts pointing to updated assumptions around revenue growth, profit margins and forward P/E to support the higher target. Valuation Changes The fair value estimate has risen from THB 26.00 to THB 32.00 per share, reflecting updated assumptions in the model.MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have reaffirmed their price target on Mega Lifesciences at THB 34.58 per share, citing unchanged assumptions for discount rate, revenue growth, profit margins, and future valuation multiples, which together support a steady outlook for the company’s fair value. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the overall equity valuation.MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have maintained their price target on Mega Lifesciences at THB 34.58 per share, reflecting steady assumptions on revenue growth, profit margins, and valuation multiples despite the latest review of fundamentals. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the core valuation thesis.MEGA: Improved Profit Margins And Revenue Estimates Suggest Fair Valuation Ahead
Analysts have raised their price target for Mega Lifesciences from THB 32.14 to THB 34.58. This reflects improved revenue growth forecasts and a slightly stronger profit margin outlook.Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets
Strategic expansion in high-growth markets and local manufacturing reduce operational risks and support sustainable revenue and margin growth.Hissedar Getirileri
| MEGA | TH Pharmaceuticals | TH Pazar | |
|---|---|---|---|
| 7D | -2.1% | -3.8% | 0.9% |
| 1Y | 39.6% | -2.6% | 40.3% |
Getiri vs. Endüstri: MEGA geçen yıl % -2.6 oranında getiri sağlayan TH Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: MEGA geçen yıl boyunca % 40.3 oranında getiri sağlayan TH Piyasası ile eşleşti.
Fiyat Oynaklığı
| MEGA volatility | |
|---|---|
| MEGA Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TH Market | 10.5% |
| 10% least volatile stocks in TH Market | 2.2% |
İstikrarlı Hisse Senedi Fiyatı: MEGA son 3 ayda TH piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: MEGA 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1982 | n/a | Vivek Dhawan | www.megawecare.com |
Mega Lifesciences Public Company Limited, bağlı ortaklıkları ile birlikte Güneydoğu Asya ve Sahra Altı Afrika'da sağlıklı gıda takviyeleri, reçeteli farmasötik ürünler, reçetesiz ürünler, bitkisel ürünler, vitaminler ve hızlı tüketim malları üretmekte ve satmaktadır. Şirket üç segmentte faaliyet göstermektedir: Markalar, Dağıtım ve Orijinal Ekipman Üretimi (OEM). Alerjiler; kan dolaşımı ve hafıza; kemik ve eklem; karaciğer ve sindirim; diyabet; göz, kalp ve cilt bakımı; ağrı, uyku, sağlık, bitkisel ve öksürük ve soğuk algınlığı için çeşitli ilaçlar ve vitaminler, probiyotikler, tıbbi ve sporcu beslenmesinin yanı sıra çocuk, erkek ve kadın bakım ürünleri sunmaktadır.
Mega Lifesciences Public Company Limited Temel Bilgiler Özeti
| MEGA temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | ฿30.73b |
| Kazançlar(TTM) | ฿2.07b |
| Gelir(TTM) | ฿14.63b |
MEGA aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| MEGA gelir tablosu (TTM) | |
|---|---|
| Gelir | ฿14.63b |
| Gelir Maliyeti | ฿6.94b |
| Brüt Kâr | ฿7.69b |
| Diğer Giderler | ฿5.62b |
| Kazançlar | ฿2.07b |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 13, 2026
| Hisse başına kazanç (EPS) | 2.37 |
| Brüt Marj | 52.55% |
| Net Kâr Marjı | 14.13% |
| Borç/Özkaynak Oranı | 4.6% |
MEGA uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/06 17:33 |
| Gün Sonu Hisse Fiyatı | 2026/06/05 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Mega Lifesciences Public Company Limited 16 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Thanapol Jiratanakij | CGS International |
| Chanpen Sirithanarattanakul | DBS Bank Ltd |
| Nantika Wiangphoem | DBS Bank Ltd |